Gameiro Mariline, Silva Renata, Rocha-Pereira Carolina, Carmo Helena, Carvalho Félix, Bastos Maria de Lourdes, Remião Fernando
UCIBIO/REQUIMTE, Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Molecules. 2017 Apr 8;22(4):600. doi: 10.3390/molecules22040600.
Adenosine triphosphate (ATP)-binding cassette (ABC) transporters are highly expressed in tumor cells, as well as in organs involved in absorption and secretion processes, mediating the ATP-dependent efflux of compounds, both endogenous substances and xenobiotics, including drugs. Their expression and activity levels are modulated by the presence of inhibitors, inducers and/or activators. In vitro, ex vivo and in vivo studies with both known and newly synthesized P-glycoprotein (P-gp) inducers and/or activators have shown the usefulness of these transport mechanisms in reducing the systemic exposure and specific tissue access of potentially harmful compounds. This article focuses on the main ABC transporters involved in multidrug resistance [P-gp, multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP)] expressed in tissues of toxicological relevance, such as the blood-brain barrier, cardiovascular system, liver, kidney and intestine. Moreover, it provides a review of the available cellular models, in vitro and ex vivo assays for the screening and selection of safe and specific inducers and activators of these membrane transporters. The available cellular models and in vitro assays have been proposed as high throughput and low-cost alternatives to excessive animal testing, allowing the evaluation of a large number of compounds.
三磷酸腺苷(ATP)结合盒(ABC)转运蛋白在肿瘤细胞以及参与吸收和分泌过程的器官中高度表达,介导内源性物质和外源性物质(包括药物)的ATP依赖性流出。它们的表达和活性水平受抑制剂、诱导剂和/或激活剂的影响。对已知和新合成的P-糖蛋白(P-gp)诱导剂和/或激活剂进行的体外、离体和体内研究表明,这些转运机制有助于降低潜在有害化合物的全身暴露和特定组织摄取。本文重点关注参与多药耐药性的主要ABC转运蛋白[P-gp、多药耐药相关蛋白1(MRP1)和乳腺癌耐药蛋白(BCRP)],这些蛋白在具有毒理学相关性的组织(如血脑屏障、心血管系统、肝脏、肾脏和肠道)中表达。此外,本文还综述了用于筛选和选择这些膜转运蛋白的安全、特异性诱导剂和激活剂的现有细胞模型、体外和离体试验。现有的细胞模型和体外试验被认为是替代过度动物试验的高通量、低成本方法,可用于评估大量化合物。